Successful rechallenge with avelumab in a patient with advanced Merkel cell carcinoma who presented pembrolizumab‐induced myositis

Successful rechallenge with avelumab in a patient with advanced Merkel cell carcinoma who presented pembrolizumab‐induced myositis

Abstract Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine skin cancer, associated with high mortality. Immune checkpoint inhibitors (ICIs) have demonstrated long‐lasting efficiency for treating advanced MCC. Despite a good safety profile, ICI remain associated with non‐negligible...

Full description

Bibliographic Details
Main Authors:	Clémence Bertold, Laura Troin, Madleen Chassang, Thierry Passeron, Jérôme Doyen, Henri Montaudié, Alexandra Picard‐Gauci
Format:	Article
Language:	English
Published:	Wiley 2023-12-01
Series:	JEADV Clinical Practice
Subjects:	immune checkpoint inhibitors immune‐related adverse events immunotherapy metastatic Merkel cell carcinoma rechallenge
Online Access:	https://doi.org/10.1002/jvc2.232

Similar Items

Recurrence of metastatic Merkel carcinoma after cessation of avelumab in a patient previously with a complete response
by: Alexandra Picard‐Gauci, et al.
Published: (2022-06-01)

Efficacy of pembrolizumab rechallenge for metastatic urothelial carcinoma
by: Nobutaka Nishimura, et al.
Published: (2022-09-01)

Cetuximab as third‐line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild‐type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials
by: G. Martini, et al.
Published: (2023-04-01)

A cost‐utility analysis of avelumab for metastatic Merkel cell carcinoma in Taiwan
by: Wen‐Cheng Chang, et al.
Published: (2021-12-01)

Budget impact model of avelumab in patients with metastatic merkel cell carcinoma in the US
by: Bharmal M, et al.
Published: (2019-05-01)

Immunotherapy Resumption/Rechallenge in Melanoma Patients after Toxicity: Do We Have Another Chance?
by: Sofia España Fernandez, et al.
Published: (2023-03-01)

Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer
by: Davide Ciardiello, et al.
Published: (2021-04-01)

The Effectiveness of Cancer Immune Checkpoint Inhibitor Retreatment and Rechallenge—A Systematic Review
by: Adrian Perdyan, et al.
Published: (2023-07-01)

Melanoma: BRAFi Rechallenge
by: Christoforos S. Kosmidis, et al.
Published: (2023-05-01)

Merkel Cell Carcinoma
by: Elena Dellambra, et al.
Published: (2021-06-01)

Clinical Outcomes, Costs, and Healthcare Resource Utilization in Patients with Metastatic Merkel Cell Carcinoma Treated with Immune Checkpoint Inhibitors vs Chemotherapy
by: Zheng Y, et al.
Published: (2021-03-01)

Safety and efficacy of cyclin-dependent kinase inhibitor rechallenge following ribociclib-induced limiting hypertransaminasemia
by: Jesús Fuentes-Antrás, et al.
Published: (2020-12-01)

Immune Checkpoint Inhibitors-Associated Myocarditis: Diagnosis, Treatment and Current Status on Rechallenge
by: Federica Frascaro, et al.
Published: (2023-12-01)

Efficacy of NSCLC Rechallenge with Immune Checkpoint Inhibitors following Disease Progression or Relapse
by: Maria Effrosyni Livanou, et al.
Published: (2024-03-01)

Taxane rechallenge during metastatic disease in HER-2 negative breast cancer patients: Clinical activity, tolerance and survival results
by: Manon Réda, et al.
Published: (2023-04-01)

CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients
by: Stefania Napolitano, et al.
Published: (2022-06-01)

Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not?
by: Heidar J. Albandar, et al.
Published: (2021-02-01)

From Merkel Cell Polyomavirus Infection to Merkel Cell Carcinoma Oncogenesis
by: Nathan A. Krump, et al.
Published: (2021-09-01)

Efficacy of taxanes rechallenge in first-line treatment of early metastatic relapse of patients with HER2-negative breast cancer previously treated with a (neo)adjuvant taxanes regimen: A multicentre retrospective observational study
by: Antoine Vasseur, et al.
Published: (2022-10-01)

Diffuse lichen planus-like keratoses and clinical pseudo-progression associated with avelumab treatment for Merkel cell carcinoma, a case report
by: Michael A. Cardis, et al.
Published: (2019-06-01)

Avelumab for the treatment of patients with Merkel cell carcinoma
by: K. V. Orlova, et al.
Published: (2020-07-01)

Hypercalcaemia due to Sarcoidosis during Treatment with Avelumab for Metastatic Merkel Cell Carcinoma
by: Sandy Tun Min, et al.
Published: (2019-08-01)

Effectiveness of EGFR‐TKI rechallenge immediately after PD‐1 blockade failure
by: Kyoichi Kaira, et al.
Published: (2021-03-01)

Skin Toxicity as Predictor of Survival in Refractory Patients with <i>RAS</i> Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy
by: Davide Ciardiello, et al.
Published: (2021-11-01)

Bell's palsy during rechallenge of immune checkpoint inhibitor
by: Kohji Takemura, et al.
Published: (2023-03-01)

Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer
by: Chiara Cremolini, et al.
Published: (2023-02-01)

Successful mRNA SARS-Cov-2 vaccine rechallenge after a first episode of immune thrombocytopenic purpura
by: Mathilde Chanut, et al.
Published: (2022-05-01)

Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis
by: Qing Zhao, et al.
Published: (2021-09-01)

Anti-EGFR Reintroduction and Rechallenge in Metastatic Colorectal Cancer (mCRC): A Real-World Analysis
by: Martin S. Schulz, et al.
Published: (2022-03-01)

Circulating Tumor DNA in Identifying Resistant Sub-Clones Post EGFR Blockade: Implications for EGFR Rechallenge
by: Adithya Chennamadhavuni, et al.
Published: (2022-06-01)

Advanced Merkel cell carcinoma in setting of pembrolizumab therapy for squamous cell carcinoma
by: Henry Jeon, BSc, et al.
Published: (2024-05-01)

PEGylated Liposomal Doxorubicin Rechallenge following Doxorubicin-induced Pancreatitis
by: Luke Ardolino, et al.
Published: (2020-12-01)

Spontaneous regression of primitive Merkel cell carcinoma
by: Fernando Cirillo
Published: (2015-12-01)

Heterogeneous Outcomes of Immune Checkpoint Inhibitor Rechallenge in Patients With NSCLC: A Systematic Review and Meta-Analysis
by: Shiting Xu, MD, et al.
Published: (2022-04-01)

Merkel Cells
Published: (2008-09-01)

Rechallenge of voriconazole successfully tolerated after hepatic toxicity
by: O. Narumoto, et al.
Published: (2020-01-01)

Immune Checkpoint Inhibitor Rechallenge in Renal Cell Carcinoma: Current Evidence and Future Directions
by: Enrico Sammarco, et al.
Published: (2023-06-01)

Merkel cell carcinoma: epidemiology, clinical features, diagnosis and treatment of a rare disease
by: Stella Meireles Siqueira, et al.
Published: (2023-06-01)

Case Report: Successful immune checkpoint inhibitor-based rechallenge in a patient with advanced renal clear cell cancer
by: Shengxiu He, et al.
Published: (2023-10-01)

Pembrolizumab-induced lichen planus pemphigoides in a patient with metastatic Merkel cell carcinoma
by: Chase W. Kwon, MD, et al.
Published: (2020-10-01)